Business Description
Mineralys Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US6031701013
Description
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.95 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -91.3 | |||||
3-Year EPS without NRI Growth Rate | -86.1 | |||||
3-Year FCF Growth Rate | -108.1 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 40.74 | |||||
9-Day RSI | 39.66 | |||||
14-Day RSI | 42.02 | |||||
6-1 Month Momentum % | 72.82 | |||||
12-1 Month Momentum % | -21.38 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 18.06 | |||||
Quick Ratio | 18.06 | |||||
Cash Ratio | 17.63 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -60.7 | |||||
Shareholder Yield % | -19.33 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -32.1 | |||||
ROA % | -30.8 | |||||
ROIC % | -694.27 | |||||
ROC (Joel Greenblatt) % | -7350.03 | |||||
ROCE % | -37.15 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 1.83 | |||||
Price-to-Tangible-Book | 1.83 | |||||
EV-to-EBIT | -5.71 | |||||
EV-to-Forward-EBIT | -2.55 | |||||
EV-to-EBITDA | -5.71 | |||||
EV-to-Forward-EBITDA | -2.56 | |||||
EV-to-FCF | -6.86 | |||||
Price-to-Net-Current-Asset-Value | 1.84 | |||||
Price-to-Net-Cash | 1.89 | |||||
Earnings Yield (Greenblatt) % | -17.51 | |||||
FCF Yield % | -14.55 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MLYS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Mineralys Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -2.21 | ||
Beta | 0 | ||
Volatility % | 76.94 | ||
14-Day RSI | 42.02 | ||
14-Day ATR ($) | 0.527473 | ||
20-Day SMA ($) | 12.5955 | ||
12-1 Month Momentum % | -21.38 | ||
52-Week Range ($) | 5.85 - 17.44 | ||
Shares Outstanding (Mil) | 49.65 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 9999 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Mineralys Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Mineralys Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Mineralys Therapeutics Inc Frequently Asked Questions
What is Mineralys Therapeutics Inc(MLYS)'s stock price today?
The current price of MLYS is $12.13. The 52 week high of MLYS is $17.44 and 52 week low is $5.85.
When is next earnings date of Mineralys Therapeutics Inc(MLYS)?
The next earnings date of Mineralys Therapeutics Inc(MLYS) is 2024-08-07 Est..
Does Mineralys Therapeutics Inc(MLYS) pay dividends? If so, how much?
Mineralys Therapeutics Inc(MLYS) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |